Johnson & Johnson (JNJ) Quick Ratio
- Quick ratio · latest quarter: Value 0.73×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-28..
Quick ratio
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 0.73× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-28. $39.80B ÷ $54.90B ≈ 0.73× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 39.80B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 54.90B USD | Liabilities, Current |
| Cash and equivalents | 20.42B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 336.00M USD | Marketable Securities, Current · Available-for-sale Securities, Current |
| Customer receivables | 19.05B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 15.14B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-28 | $39.80B | $54.90B | $20.42B | $336.00M | $19.05B | $15.14B | 0.73× |
| 2026-03-29 | $39.77B | $57.72B | $21.69B | $363.00M | $17.72B | $14.58B | 0.69× |
| 2025-12-28 | $37.28B | $54.13B | $19.71B | $393.00M | $17.18B | $14.19B | 0.69× |
| 2025-09-28 | $36.17B | $50.87B | $18.23B | $331.00M | $17.61B | $14.15B | 0.71× |
| 2025-06-29 | $36.73B | $54.18B | $18.58B | $303.00M | $17.85B | $13.41B | 0.68× |
| 2025-03-30 | $54.80B | $56.90B | $38.47B | $307.00M | $16.02B | $12.66B | 0.96× |
| 2024-12-29 | $39.36B | $50.32B | $24.11B | $417.00M | $14.84B | $12.44B | 0.78× |
| 2024-09-29 | $36.47B | $51.76B | $19.98B | $317.00M | $16.17B | $12.60B | 0.70× |
| 2024-06-30 | $41.27B | $53.93B | $24.88B | $597.00M | $15.79B | $12.17B | 0.77× |
| 2024-03-31 | $41.16B | $48.73B | $25.47B | $745.00M | $14.95B | $11.38B | 0.84× |
| 2023-12-31 | $37.80B | $46.28B | $21.86B | $1.07B | $14.87B | $11.18B | 0.82× |
| 2023-10-01 | $38.31B | $44.37B | $19.73B | $3.78B | $14.80B | $11.20B | 0.86× |
| 2023-07-02 | $45.28B | $54.17B | $21.18B | $7.32B | $16.78B | $12.89B | 0.84× |
| 2023-04-02 | $40.96B | $60.37B | $19.17B | $5.44B | $16.35B | $12.81B | 0.68× |
| 2023-01-01 | $39.68B | $55.80B | $14.13B | $9.39B | $16.16B | $12.48B | 0.71× |
| 2022-10-02 | $49.97B | $45.54B | $11.36B | $22.72B | $15.89B | $11.68B | 1.10× |
| 2022-07-03 | $48.71B | $44.82B | $10.98B | $21.59B | $16.14B | $11.44B | 1.09× |
| 2022-04-03 | $45.98B | $43.39B | $10.46B | $19.93B | $15.59B | $10.99B | 1.06× |
| 2022-01-02 | $46.89B | $45.23B | $14.49B | $17.12B | $15.28B | $10.39B | 1.04× |
| 2021-10-03 | $45.91B | $44.56B | $17.60B | $13.40B | $14.91B | $10.39B | 1.03× |
| 2021-07-04 | $40.18B | $38.72B | $14.33B | $10.97B | $14.87B | $10.10B | 1.04× |
| 2021-04-04 | $39.56B | $40.93B | $12.67B | $11.95B | $14.94B | $9.95B | 0.97× |
| 2021-01-03 | $38.76B | $42.49B | $13.98B | $11.20B | $13.58B | $9.34B | 0.91× |
| 2020-09-27 | $45.36B | $38.85B | $18.96B | $11.82B | $14.58B | $9.60B | 1.17× |
| 2020-06-28 | $33.78B | $36.77B | $11.17B | $7.96B | $14.64B | $9.42B | 0.92× |
| 2020-03-29 | $32.90B | $33.69B | $15.53B | $2.49B | $14.87B | $8.87B | 0.98× |
| 2019-12-29 | $33.77B | $35.96B | $17.30B | $1.98B | $14.48B | $9.02B | 0.94× |
| 2019-09-29 | $32.75B | $35.16B | $16.25B | $1.70B | $14.80B | $9.17B | 0.93× |
| 2019-06-30 | $29.93B | $31.35B | $14.38B | $902.00M | $14.65B | $9.26B | 0.95× |
| 2019-03-31 | $29.45B | $29.11B | $14.73B | $602.00M | $14.12B | $9.09B | 1.01× |
| 2018-12-30 | $33.78B | $31.23B | $18.11B | $1.58B | $14.10B | $8.60B | 1.08× |
| 2018-09-30 | $33.41B | $27.44B | $16.06B | $3.31B | $14.05B | $8.68B | 1.22× |
| 2018-07-01 | $32.25B | $27.49B | $17.57B | $570.00M | $14.11B | $8.81B | 1.17× |
| 2018-04-01 | $29.37B | $27.08B | $14.64B | $565.00M | $14.17B | $9.01B | 1.08× |
| 2017-12-31 | $31.79B | $30.54B | $17.82B | $472.00M | $13.49B | $8.77B | 1.04× |
| 2017-10-01 | $29.39B | $31.81B | $15.72B | $510.00M | $13.15B | $9.52B | 0.92× |
| 2017-07-02 | $26.14B | $28.87B | $12.60B | $255.00M | $13.28B | $9.70B | 0.91× |
| 2017-04-02 | $51.64B | $25.12B | $20.91B | $18.43B | $12.30B | $8.88B | 2.06× |
| 2017-01-01 | $53.61B | $26.29B | $18.97B | $22.93B | $11.70B | $8.14B | 2.04× |
| 2016-10-02 | $52.23B | $23.23B | $18.20B | $22.23B | $11.80B | $8.49B | 2.25× |
| 2016-07-03 | $54.65B | $21.54B | $18.64B | $23.94B | $12.06B | $8.52B | 2.54× |
| 2016-04-03 | $51.26B | $22.13B | $13.86B | $25.99B | $11.41B | $8.17B | 2.32× |
| 2016-01-03 | $49.11B | $27.75B | $13.73B | $24.64B | $10.73B | $8.05B | 1.77× |
| 2015-09-27 | $48.67B | $25.26B | $13.64B | $23.67B | $11.37B | $8.21B | 1.93× |
| 2015-06-28 | $45.92B | $24.51B | $10.64B | $23.32B | $11.97B | $8.30B | 1.87× |
| 2015-03-29 | $42.85B | $23.84B | $11.99B | $19.33B | $11.53B | $8.09B | 1.80× |
| 2014-12-28 | $44.07B | $25.09B | $14.52B | $18.57B | $10.98B | $8.18B | 1.76× |
| 2014-09-28 | $44.62B | $22.98B | $13.82B | $19.19B | $11.62B | $8.42B | 1.94× |
| 2014-06-29 | $43.88B | $24.36B | $14.24B | $17.39B | $12.26B | $8.15B | 1.80× |
| 2014-03-30 | $41.51B | $23.84B | $19.72B | $9.67B | $12.12B | $8.01B | 1.74× |
| 2013-12-29 | $40.92B | $25.68B | $20.93B | $8.28B | $11.71B | $7.88B | 1.59× |
| 2013-09-29 | $37.26B | $25.84B | $17.20B | $8.02B | $12.03B | $8.12B | 1.44× |
| 2013-06-30 | $36.74B | $23.77B | $17.31B | $7.82B | $11.61B | $7.82B | 1.55× |
| 2013-03-31 | $33.18B | $22.52B | $14.86B | $6.81B | $11.52B | $7.69B | 1.47× |
| 2012-12-30 | $32.40B | $24.26B | $14.91B | $6.18B | $11.31B | $7.50B | 1.34× |
| 2012-09-30 | $30.95B | $23.93B | $15.49B | $4.29B | $11.18B | $7.81B | 1.29× |
| 2012-07-01 | $27.91B | $23.85B | $14.04B | $2.87B | $10.99B | $7.70B | 1.17× |
| 2012-04-01 | $44.83B | $21.20B | $30.27B | $3.58B | $10.98B | $6.80B | 2.11× |
| 2012-01-01 | $42.84B | $22.81B | $24.54B | $7.72B | $10.58B | $6.29B | 1.88× |
| 2011-10-02 | $41.48B | $21.69B | $15.62B | $15.31B | $10.55B | $6.43B | 1.91× |
| 2011-07-03 | $40.66B | $20.98B | $14.97B | $14.71B | $10.98B | $6.41B | 1.94× |
| 2011-04-03 | $37.73B | $24.01B | $22.36B | $4.51B | $10.86B | $6.20B | 1.57× |
| 2011-01-02 | $37.43B | $23.07B | $19.36B | $8.30B | $9.77B | $5.38B | 1.62× |
| 2010-10-03 | $32.42B | $17.41B | $14.34B | $7.79B | $10.29B | $5.41B | 1.86× |
| 2010-07-04 | $28.53B | $17.16B | $12.71B | $6.19B | $9.63B | $5.07B | 1.66× |
| 2010-04-04 | $28.03B | $18.50B | $13.74B | $4.27B | $10.02B | $5.31B | 1.52× |
| 2010-01-03 | $29.07B | $21.73B | $15.81B | $3.62B | $9.65B | $5.18B | 1.34× |
| 2009-09-27 | $24.62B | $19.25B | $11.86B | $2.48B | $10.28B | $5.57B | 1.28× |
| 2009-06-28 | $24.85B | $19.89B | $11.69B | $3.03B | $10.13B | $5.47B | 1.25× |
| 2009-03-29 | (m) | (m) | $12.59B | (m) | (m) | (m) | (m) |
| 2008-12-28 | $22.53B | $20.85B | $10.77B | $2.04B | $9.72B | $5.05B | 1.08× |
| 2008-09-28 | (m) | (m) | $14.02B | (m) | (m) | (m) | (m) |
| 2008-06-29 | (m) | (m) | $12.65B | (m) | (m) | (m) | (m) |
| 2007-12-30 | (m) | (m) | $7.77B | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | $4.08B | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |